Pneumococcal Disease- Prophylaxis
First Line Drugs
- PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED (J07AL02)
Pneumococcal polysaccharide vaccine
0.5 mL SC or IM, 1 dose
-Vaccination is recommended for all people 65 years and older; adults and children 2 years of age and older with asplenia, splenic dysfunction, sickle-cell disease, nephrotic syndrome, chronic cerebrospinal fluid leak, HIV infection and other conditions associated with immunosuppression; and adults with chronic cardiorespiratory disease, cirrhosis, alcoholism, chronic renal disease and diabetes.
-The duration of protection from the vaccine is unknown but is likely as long as 5 years.
-Revaccination is recommended at 6 years for patients at particularly high risk for pneumococcal infection, e.g., those with asplenia and transplant recipients.
-Efficacy of the vaccine in preventing invasive pneumococcal disease in immunocompetent people is greater than 80% in healthy young adults but in the elderly it is in the range of 50-60%. The vaccine does not appear to be effective in the prevention of pneumonia overall or of pneumococcal pneumonia in middle-aged and elderly people who are not in institutions.
- Respiratory System